Ophthalmic preparation

Through the combination of poloxamer and quaternized chitosan, a temperature-sensitive loose porous gel is formed, which solves the compatibility problem of existing ophthalmic preparations between eye drops and eye ointments, and achieves drug relief Release and antibacterial effects improve eye retention time and bioavailability.

CN118986856APending Publication Date: 2024-11-22MACAU UNIV OF SCI & TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411120834.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing ophthalmic preparations are difficult to take into account the fluidity of eye drops and the corneal adhesion of eye ointments, and lack loose porous structure and antibacterial properties, resulting in short retention time of the drug in the eyes, low bioavailability and risk of side effects.

Method used

Poloxamer and quaternized chitosan are combined to form a temperature-sensitive loose porous supramolecular gel, which enhances water absorption and moisturizing ability, and achieves drug relief through the combination of poloxamer and quaternized chitosan. Release and antibacterial effects.

Benefits of technology

It improves the retention time and bioavailability of the drugs in the eyes, reduces the risk of side effects, enhances the adsorption and antibacterial ability of the gel, and improves the treatment compliance of patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118986856A_ABST
    Figure CN118986856A_ABST
Patent Text Reader

Abstract

The invention belongs to a medical material and medicine dosage form technology, and particularly relates to an ophthalmic preparation which contains a medicine, poloxamer and quaternized chitosan and takes water as a solvent, the ophthalmic preparation can give consideration to the flowability of eye drops and the cornea adhesive force of eye ointment, and meanwhile, the ophthalmic preparation has a loose porous structure, can load medicine molecules and has antibacterial property.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to medical materials and pharmaceutical dosage form technology, specifically a pharmaceutical preparation which can take into account the fluidity of eye drops and the corneal adhesion of eye ointments, and at the same time has a loose porous structure capable of loading drug molecules and has antibacterial properties. Background Art

[0002] Many eye diseases, such as glaucoma, corneal infection and inflammation, will eventually lead to serious consequences of blindness if they are not treated promptly and effectively. The use of appropriate drugs can effectively control the disease, relieve or eliminate symptoms, and choosing a reasonable dosage form to ensure the safety and effectiveness of the drug and make it acceptable to patients is an important issue in drug treatment.

[0003] According to statistics, solution-type eye drops account for more than 60% of the ophthalmic preparations on the market. They are popular among patients because of their convenience, rarely causing blurred vision and low price. The eyes are very sensitive organs. The elimination of foreign bodies by protective mechanisms such as tearing and blinking leads to a short retention time of drugs in the conjunctival sac and low local bioavailability, which hinders the efficacy of drugs. In addition, most drugs reach the nasal cavity with tears and then enter the systemic circulation through the mucous membrane, increasing the risk of side effects. Eye ointments or gels can significantly block the elimination of drugs, prolong the corneal retention time of drugs, and thus improve their local bioavailability, but the higher viscosity causes problems such as difficulty in preparation, inaccurate dosage and inconvenient use, which seriously limits the development of such dosage forms.

[0004] The development of ophthalmic preparations with both long-lasting effects and good compliance has always been an important challenge for the rational use of ophthalmic drugs. The in situ gel drug delivery system is a novel dosage form that utilizes the sensitivity of polymers to environmental factors, delivers drugs in a solution state, and forms a gel locally. It combines the advantages of solutions and gels while avoiding their shortcomings, showing ideal and application prospects.

[0005] The ABA block copolymer of polyoxyethylene / polyoxypropylene, with the non-patent name poloxamer, is a high-molecular-weight excipient included in the pharmacopoeia, which has high safety, no irritation and allergy, and good biocompatibility. A certain concentration of poloxamer aqueous solution has the property of reverse gelation when heated, that is, it is a free-flowing liquid at refrigerated temperature and forms a clear gel at room temperature or body temperature. Poloxamer can be used to prepare in-situ gel for eyes, but the ideal solution-gel transition temperature cannot be obtained by using a single type of poloxamer. For example, 25% (w / w) poloxamer 407 forms a gel at room temperature and needs to be refrigerated to convert it into a liquid before it can be used. This not only brings great inconvenience to patients' medication, but also the too low temperature of the preparation causes irritation to the eyes, causing physiological reverse promotion of drug elimination such as tearing and blinking, which is not conducive to improving the local bioavailability of the drug.

[0006] A patent reported that the combination of pH-sensitive carbomer and poloxamer can obtain a gel with a suitable phase transition temperature and good rheological properties, but the preparation is acidic and needs to be neutralized by tears to form a gel, which may cause discomfort after use. Another patent reported that by using two different types of poloxamers in combination, the gel phase transition temperature can be adjusted to above room temperature (25°C), and the preparation can still form a gel at body temperature (35°C) after being diluted by tears, but the viscosity, swelling rate and antibacterial activity of the preparation cannot be guaranteed.

[0007] Therefore, there is an urgent need to provide a drug preparation that can take into account the fluidity of eye drops and the corneal adhesion of eye ointments, and at the same time has a loose porous structure that can load drug molecules and has antibacterial properties. Summary of the invention

[0008] The present invention aims to solve one of the technical problems existing in the prior art to a certain extent at least. To this end, the present invention provides an ophthalmic preparation containing a drug, poloxamer, quaternized chitosan, and water as a solvent.

[0009] Preferably, the poloxamer is poloxamer 407 and poloxamer 188.

[0010] Preferably, the quaternized chitosan is N-(2-hydroxy)-propyl-3-trimethyl chitosan chloride.

[0011] Preferably, the preparation has a porous structure, and the proportion of pores with diameters between 1 and 2 μm accounts for at least more than 50%.

[0012] Preferably, the poloxamer 407 accounts for 21.5% of the total weight of the preparation, the poloxamer 188 accounts for 6.5%, the N-(2-hydroxy)-propyl-3-trimethyl chitosan chloride accounts for 0.5-0.7%, and the proportion of pores with a diameter between 1-2 μm is at least more than 55%.

[0013] The present invention provides a novel in-situ gel for eye drug administration with temperature sensitivity and antibacterial ability, which can realize corneal sustained-release drug administration. The method combines a certain proportion of poloxamer and quaternized chitosan, utilizes the high-temperature gel property of the substance, forms a loose porous supramolecular gel capable of loading drugs, and enhances the water absorption and moisture retention capacity of the gel. At the same time, after the gel is loaded with drugs, the drugs need to break through the constraints of the gel and release to achieve a sustained-release effect. Poloxamer and quaternized chitosan are complementary and mutually reinforcing, and their properties are mutually utilized to enrich the advantages of the overall gel. Both poloxamer and quaternized chitosan are non-toxic materials with high biocompatibility. They can keep cells alive in corneal epithelial cells, will not cause a series of hypersensitivity reactions, reduce nasolacrimal duct drainage, and improve the bioavailability of drugs. The introduction of the temperature-sensitive in-situ gel can effectively reduce the utilization rate of other low-drug utilization dosage forms and improve the treatment compliance of patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] The drawings described herein are used to provide a further understanding of the present invention and constitute a part of this application. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation of the present invention. In the drawings:

[0015] Figure 1 The synthesis mechanism of HTCC provided according to an embodiment of the present invention is shown;

[0016] Figure 2 The FT-IR spectra of (a) HTCC at room temperature, (b) CS and HTCC, and (c) HTCC are shown in FIG. 1 H-NMR spectrum, (d) the relationship between the conductivity of HTCC solution and the volume of AgNO3;

[0017] Figure 3 Shown are (a) the chemical structure of poloxamer, (b) the gelation mechanism of in situ Po-HTCC gel, (c) the molecular structure of in situ Po-HTCC gel and its application in ocular drug delivery, and (d) the mechanism of interaction between HTCC and corneal mucin provided by embodiments of the present invention;

[0018] Figure 4Shown are (a) response surfaces of P407 and P188 concentrations at gelation temperatures, (b) response surfaces of P407 and HTCC concentrations at gelation temperatures, (c) response surfaces of P188 and HTCC concentrations at gelation temperatures, (d) Po-HTCC in-situ gelation at 4°C, (e) Po-HTCC in-situ gelation at 34°C, (f) changes in swelling ratio of freeze-dried PoHTCC hydrogel and Po hydrogel in STF over time, and (g) viscosity change curves of Po-HTCC hydrogel and Po hydrogel during changes in external ambient temperature from 8°C to 34°C according to embodiments of the present invention;

[0019] Figure 5 shows SEM micrographs of Po-HTCC and Po hydrogel at different magnifications provided according to an embodiment of the present invention;

[0020] Figure 6 The figures show (a) cell viability of HCE-T cells in a Po-HTCC hydrogel environment according to an embodiment of the present invention; (b) morphology of HCE-T cells observed under an electron microscope; (c) release curve of levofloxacin hydrochloride in each sample within 72 hours; (d) ZOI in bacterial culture medium; (e) ZOI comparison diagram of each sample;

[0021] Figure 7 The binding patterns of HTCC with five proteins (LptE (RlpB), LptD-LptE, MUC1SEA domain, MUC16 SEA5 domain and MUC5AC CysD7 domain) obtained by molecular docking according to an embodiment of the present invention are shown. DETAILED DESCRIPTION

[0022] The following examples are provided to allow those skilled in the art to more clearly understand the present invention. It should be noted that the following examples do not limit the scope of protection claimed in the present invention and are only illustrative examples. The raw materials, reagents or devices mentioned in the following examples, unless otherwise specified, can be obtained from commercial sources or by known existing methods.

[0023] Example 1: Synthesis of N-(2-hydroxy)-propyl-3-trimethyl chitosan chloride (HTCC)

[0024] Glycidyl trimethylammonium chloride (GTMAC) (2.82 g) was dissolved in 30 mL of deionized water, chitosan (CS) (1.0 g) was dispersed in the GTMAC solution, and then stirred and refluxed at 500 rpm and 80 ° C for 5 hours. After the reaction was completed, the light yellow solution was poured into four times the volume of cold acetone, and a white solid was precipitated. The solid was filtered out and washed with cold acetone. The solid product was placed in 50 mL of anhydrous ethanol and stirred at 4 ° C overnight to disperse the particles. After stirring overnight, the white precipitate was filtered out, and the product was dried in an oven at 50 ° C overnight to obtain HTCC. The HTCC was washed in hot ethanol for 12 hours by a Soxhlet extractor, and then filtered to obtain purified HTCC, which was then dried at 50 ° C overnight to obtain a purer HTCC. Figure 1 The synthesis mechanism of HTCC is shown. Figure 2 (a) is the morphology of HTCC at room temperature, (b) is the FT-IR spectra of CS and HTCC, and (c) is the morphology of HTCC. 1 H-NMR spectrum, (d) is the relationship between the conductivity of HTCC solution and the volume of AgNO3. The degree of substitution (DS) is the ratio of hydrogen atoms replaced on -NH2. The Cl in HTCC is determined by AgNO3 titration - Dissolve 20 mg HTCC in 150 mL 0.01 M lactic acid solution, slowly drip into 0.004 M AgNO3(c) solution, use a digital conductivity meter to record the change in conductivity in the solution, and record the volume of AgNO3(V) consumed when the solution conductivity is the lowest (10.96 ml), and use the following formula to calculate the DS of HTCC:

[0025] DS=cV / (cV+(1000W-314cV) / 162)ⅹ1 / DDⅹ100%

[0026] V / mL is the volume of AgNO3 used, c / mol·L -1 is the concentration of AgNO3 solution, DD is the deacetylation degree of chitosan (DD=95%), W / g is the weight of HTCC, 162 and 314 are the molecular weights of CS and HTCC monomers, respectively.

[0027] Example 2: Preparation of Po-HTCC hydrogel

[0028] Poloxamer (Po) is a triblock copolymer of polyethylene oxide-b-polypropylene oxide-b-polyethylene oxide (PEO-PPO-PEO). Figure 3(a) is the chemical structure of poloxamer, the most common poloxamers are P188 and P407. Poloxamers are good thermosensitive gel materials. Due to their good water solubility, solution transparency and biocompatibility, they are widely used to develop thermosensitive gel delivery materials for the eye. However, their insufficient mechanical properties limit the adhesion of the preparation on the mucosal surface. Poloxamers have a variety of applications in ocular drug delivery systems, including the treatment of corneal burns, corneal inflammation, bacterial infections of the eye, glaucoma, etc.

[0029] The prior art provides an ophthalmic in-situ gel preparation with a suitable phase transition temperature, which contains a water-soluble polymer excipient. By using two different types of poloxamers in combination, the phase transition temperature is adjusted to above room temperature (25°C), and the preparation can still form a gel at body temperature (35°C) after being diluted by tears. According to the type of poloxamer used and the ratio between different types of poloxamers, the phase transition temperature of the preparation can be adjusted to between 25-30°C. Further increasing the phase transition temperature causes the preparation to no longer form a gel at 35°C after being diluted by tears. The poloxamers involved in the preparation are poloxamer 407 and poloxamer 188, of which poloxamer 407 accounts for 15%-25% (w / w), poloxamer 188 accounts for 5%-25% (w / w), and water accounts for 80%-50%.

[0030] However, according to the technical solutions given in the prior art, although the temperature-sensitive properties of poloxamer aqueous solutions and the combination of different types of poloxamers are used to prepare an ophthalmic in-situ gel preparation with a suitable phase transition temperature, so that it can be administered in a liquid state at room temperature and form a gel on the corneal surface, its mechanical properties are still insufficient, which limits the adhesion of the preparation on the mucosal surface, and the sustained release effect of the drug is not good (long-acting release preparations can continuously release drugs for weeks or months. Long-acting administration can improve drug efficacy and safety by maintaining the drug level at an optimal concentration (not lower than the minimum therapeutic concentration or not exceeding the safety threshold concentration)).

[0031] Box-Behnken Design (BBD) was constructed based on Design-Expert software (version 13, Stat-Ease Inc., Minneapolis, MN, USA) to optimize the gelation temperature of in situ gelation. In the optimization experiment, 17 BBD runs were constructed for three formulation factors (P407, P188 and HTCC) studied at three levels (-1, 0 and +1). First, a specified amount of HTCC was charged into a bottle, deionized water was added, and it was slowly stirred at 4°C to dissolve. Then, a specified amount of P407 and P188 were added to the completely dissolved HTCC solution, and then placed at 4°C overnight to dissolve it to obtain a thermosensitive gel solution. Figure 3 (b) shows the gelation mechanism of in situ Po-HTCC gel. Figure 3 (c) shows the molecular structure of in situ Po-HTCC gel and its application in ocular drug delivery, and Figure 3 (d) shows the mechanism of interaction between HTCC and corneal mucin.

[0032] A certain proportion of poloxamer and quaternized chitosan are combined, and the high-temperature gel properties of the material are utilized to form a loose porous supramolecular gel that can load drugs, thereby enhancing the water absorption and moisture retention capacity of the gel. At the same time, after the gel is loaded with drugs, the drugs need to break through the constraints of the gel to release and achieve a sustained release effect. Both poloxamer and quaternized chitosan are non-toxic materials with high biocompatibility. They can keep cells alive in corneal epithelial cells, will not cause a series of hypersensitivity reactions, reduce nasolacrimal duct drainage, and improve the bioavailability of drugs. The introduction of thermosensitive in situ gel can effectively reduce the use rate of other low drug utilization dosage forms and improve patients' treatment compliance.

[0033] Example 3: Determination of the gel temperature and optimal ratio of Po-HTCC in-situ gel

[0034] The gelation temperature of Po-HTCC in situ gel was determined using the test tube inversion method (TTM). Prepare 3 mL of Po-HTCC in situ gel and place it in a vial. Place the vial in a 37°C water bath. Take out the vial and rotate it 180° every 10 seconds. When the gel solution in the vial no longer flows, measure the gelation temperature using a sensitive probe thermometer (DeltaTRAK11040, USA). All 17 groups of gel solutions designed by Design-Expert software use the same method to measure the gelation temperature. Use BBD to optimize the optimal gelation temperature. After measuring the 17 groups of gel temperatures, use Design-Expert software for analysis, draw a response surface plot of the relationship between the factors, and calculate the multi-factor binomial regression equation to predict the optimal gelation temperature. The formula is as follows:

[0035] T=β0+β1A+β2B+β3C+β 12 AB+β 23 BC+β 13 AC+β 11 A 2 +β 22 B 2 +β 33 C 2

[0036] T is the dependent variable of gel temperature, A, B and C are the independent variables P407, P188, HTCC, and β0 is the arithmetic mean response of 17 runs. i and β ij(I, j = 1-3) are the coefficients of the individual linear effect and quadratic effect of the factor, respectively. The final optimal gel temperature formula obtained after optimization is P407: 21.5%, P188: 6.5%, HTCC: 0.6%, T: 30.92°C. 3 different proportions of HTCC controls were set, HTCC: 0.5% (Gel1), 0.6% (Gel2), 0.7% (Gel3).

[0037] Figure 4 (a) shows the response surface of P407 and P188 concentrations at gelling temperature. Figure 4 (b) shows the response surface of P407 and HTCC concentration at gelation temperature. Figure 4 (c) shows the response surface of P188 and HTCC concentration at gelation temperature. Figure 4 (d) is the Po-HTCC in situ gel at 4°C. Figure 4 (e) is the Po-HTCC in situ gel at 34°C.

[0038] Example 4: Swelling capacity test

[0039] The swelling properties were studied by measuring the water absorption of Po-HTCC and Po in situ gels in simulated tear fluid (STF). STF was prepared with 6.7 g of NaCl, 2.0 g of NaHCO3 and 0.08 g of CaCl2·H2O, and the pH was adjusted to 7.4 with 0.5 mol / L HCl solution. About 5 g of the gel solution was taken and incubated at 34°C to form a gel, which was then freeze-dried and the initial mass W0 (g) was recorded. Subsequently, the sample was immersed in 25 mL of the pre-prepared STF and incubated at 34°C for 5 h. The sample was taken out every hour, and the excess water on the surface of the gel was carefully removed with filter paper. The sample was weighed to record the mass W at different times. t (g). The results show that Po-HTCC hydrogels have larger pores and more pores compared to Po hydrogels. This structural difference gives Po-HTCC hydrogels a greater ability to adsorb water molecules. The increased porosity of Po-HTCC hydrogels also facilitates the transport of small molecules through the hydrogel matrix. Therefore, Po-HTCC hydrogels exhibit higher water content, which is more conducive to the movement and diffusion of small molecules within the hydrogel network. Compared with the three gels with different HTCC ratios, the higher the HTCC content, the greater the swelling rate. Figure 4 (f) Changes in the swelling ratio of freeze-dried Po-HTCC hydrogel and Po hydrogel in STF over time.

[0040] Example 5: Viscosity Test

[0041] A certain amount of in-situ gel sample was placed in a rheometer with an initial temperature of 12°C, and the viscosity of Po-HTCC in-situ gel and Po in-situ gel was measured as the temperature increased from 12°C to 34°C. The shear rate was set to 20s -1 . The viscosity of the four samples followed a similar trend, with low viscosity at approximately 8-28°C and a sudden and significant increase in viscosity after approximately 28°C, indicating that the transition from liquid to gel began to occur at this temperature, which is consistent with the previous gel temperature test results. For Po-HTCC hydrogels, the addition of HTCC significantly increased the viscosity of the hydrogel, which may be attributed to the enhanced hydrophobic interactions through the addition of HTCC, thereby improving the mechanical strength of the poloxamer system. The viscosity of both the solution and gel forms increased significantly, which is critical for enhancing the adhesion of the material to the cornea. Figure 4 (g) is the viscosity change curve of Po-HTCC hydrogel and Po hydrogel when the external environment temperature changes from 8°C to 34°C.

[0042] Example 6: SEM scanning electron microscope test experiment

[0043] The structural-morphological characteristics of HTCC-Po, HTCC-Po-LF and Po in situ gels formed at 34°C were analyzed by scanning electron microscopy (SEM). After the hydrogels were freeze-dried, the microstructures of the three gels were observed at an accelerating voltage of 2.00 kV.

[0044] Three sets of magnifications of 10,000 times, 5,000 times, and 2,000 times were set to observe the internal structure of the hydrogel material. The prepared hydrogel has a uniform loose porous structure, and each pore is regularly interconnected with its surroundings. Comparing the HTCC-Po gel with the Po gel, it can be seen that the HTCC-Po hydrogel has a larger macropore size and a larger macropore density, as well as a thicker pore wall. The macropores in the Po-HTCC in-situ gel are mainly concentrated in the range of 1-2 μm. At 10,000 times, 5,000 times, and 2,000 times magnification, this size range accounts for approximately 63.64%, 57.78%, and 64.09%, respectively, with an average percentage of 61.84%. Figure 5 SEM micrographs of Po-HTCC and Po hydrogels at different magnifications: (a) 10000×, (b) 5000× and (c) 2000× magnifications of Po-HTCC hydrogel. (d) 10000×, (e) 5000× and (f) 2000× magnifications of Po hydrogel. (g), (h) and (i) Distribution of macropores in Po-HTCC in situ gel at three magnifications. The proportion of pores with diameters between 1-2 μm is more than 50% at all three magnifications.

[0045] Example 7: Cytotoxicity experiment of Po-HTCC in situ gel

[0046] The hydrogel samples were immersed in a human corneal epithelial cell (HCE-T)-specific culture medium and incubated at 37°C for 12 hours. Subsequently, the culture medium was filtered through a filter membrane to remove the hydrogel residue and prepared for use. HCE-T was seeded in a 96-well plate at a density of 4000 cells per well and incubated overnight. Subsequently, the culture medium was removed and three different groups of hydrogel culture media were added, the cells were exposed to a 100 μL hydrogel culture medium environment, and the cells were further incubated at 37°C in a 5% CO2 atmosphere for 48 hours. After the incubation was completed, the cell activity was determined using a CCK-8 kit, and 10 μL CCK-8 was added to each well, followed by incubation at 37°C in 5% CO2 for 2 hours. Cell activity was detected using an enzymatic method. The absorbance of each culture medium at 450 nm was measured using an enzyme marker to calculate the percentage of live cells. The final results showed that the cell viability of the formulas P407:21.5%, P188:6.5%, and HTCC:0.6% reached more than 90%, and the cell viability of other formulas was lower than that of this formula. Figure 6 (a) Cell viability of HCE-T cells in Po-HTCC hydrogel environment; (b) HCE-T cell morphology observed under electron microscope.

[0047] Example 8: In vitro drug release experiment of levofloxacin hydrochloride (LF)

[0048] In vitro drug release studies were performed using the dialysis bag method. Three groups of samples, Po-HTCC-LF, Po-LF and LF aqueous solutions, 1 mL each, were prepared and added to dialysis bags (8-14 kDa). Three bottles of 100 mL of simulated tear fluid (STF) were prepared as release media, and dialysis bags were placed in each vial. Three bottles of 100 mL of STF were prepared as release media, dialysis bags were placed in each vial, and then the three bottles were placed in a constant temperature oscillator at 34°C and continuously oscillated at 100 rpm for in vitro drug release studies. At different time points (0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 7, 8, 24, 48 and 72 hours), 3 mL of STF was taken out and the vials were replenished with an equal amount of fresh STF. The content of LF in the samples was determined by an ultraviolet spectrophotometer (UV-2600i Shimadzu, Japan). The final results showed that the P407:21.5%, P188:6.5%, HTCC:0.6% formula gel had better drug sustained release ability than pure Po gel and ordinary aqueous solution. Figure 6 (c) shows the release profile of levofloxacin hydrochloride in each sample within 72 h.

[0049] Example 9: Antibacterial ability test

[0050] The antibacterial ability of Po-HTCC gel was studied using Escherichia coli and Staphylococcus aureus. The antibacterial ability was evaluated by measuring the size of the inhibition zone (ZOI) produced by the gel in the culture medium using the filter paper diffusion method. TSB solid medium was prepared by mixing TSB medium with agar powder. 100 μL of 1×10 8 The colony forming unit (CFUs) bacterial suspension was evenly spread on the culture medium, and 8 sterilized filter papers with a diameter of about 6 mm were taken and soaked in Po-HTCC-LF gel, Po-HTCC gel, Po gel, and LF aqueous solution for 1 minute respectively to wet the filter paper. The drug concentration of all samples containing levofloxacin hydrochloride was 0.2% (w / w). The wet filter paper was placed flat on the center of the TSB culture medium and incubated in a constant temperature incubator at 37°C for 24 hours, and the ZOI width was measured. The results showed that the ZOI of Po-HTCC-LF gel was the largest, followed by the LF aqueous solution, the ZOI of Po-HTCC gel was smaller, and the Po hydrogel had almost no ZOI, proving that HTCC has a certain antibacterial ability. Figure 6 (d) shows ZOI in bacterial culture medium and Figure 6 (e) shows a comparison graph of the ZOI of each sample.

[0051] Example 10: Molecular docking test

[0052] Molecular docking was used to determine the binding ability of HTCC to related proteins in the outer membrane of E. coli and major mucins in the cornea. The proteins selected for molecular docking were the outer membrane lipopolysaccharide transporter LptE (RlpB) from E. coli K-12 and the outer membrane lipopolysaccharide assembly complex LptD-LptE. Mucins are derived from the MUC1 SEA domain, MUC16 SEA5 domain, and MUC5AC CysD7 domain of human cornea and conjunctiva. All 3D crystal structures of all proteins were obtained from the Protein Data Bank (RCSB PDB). In this study, AutoDock Vina 1.1.2 software was used for molecular docking. Before docking began, the receptor protein was processed using PyMol 2.5.5, including the removal of water molecules, salt ions and small molecules. Subsequently, the docking box was set up so that it was wrapped around the entire protein structure. In addition, all processed small molecules and receptor proteins were converted into the PDBQT format required for AutoDock Vina 1.1.2 docking using ADFRsuite1.0. During docking, the exhaustiveness of the global search was set to 32, and the other parameters remained at the default settings. The docking conformation with the highest score was considered as the binding conformation, and the docking results were finally visualized using PyMol 2.5.5. The results showed that the binding affinities of HTCC to LptE (RlpB) and LptD-LptE were -4.8 kcal / mol and -7.5 kcal / mol, respectively, which means that HTCC has the potential to bind to LptE (RlpB) and LptD-LptE proteins, and the binding to LptD-LptE is better. In summary, the molecular docking results of HTCC with Escherichia coli lipopolysaccharide-related proteins are consistent with the results of the antibacterial test, indicating that HTCC has antibacterial activity. The binding affinities of HTCC to MUC5AC, MUC16 and MUC1 are -5.1 kcal / mol, -5.5 kcal / mol and -5.6 kcal / mol, respectively, which means that HTCC has the potential to bind to all three mucins. Figure 7 The binding modes of HTCC to five proteins (LptE (RlpB), LptD-LptE, MUC1 SEA domain, MUC16 SEA5 domain and MUC5AC CysD7 domain) obtained by molecular docking are shown.

[0053] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. An ophthalmic preparation, characterized in that It contains drugs, poloxamer, quaternized chitosan, and uses water as solvent.

2. The preparation according to claim 1, characterized in that The poloxamers are poloxamer 407 and poloxamer 188.

3. The preparation according to claim 1, characterized in that The quaternized chitosan is N-(2-hydroxy)-propyl-3-trimethyl chitosan chloride.

4. The preparation according to claim 1, characterized in that The preparation has a porous structure, and the proportion of pores with diameters between 1 and 2 μm is at least more than 50%.

5. The preparation according to claim 1, characterized in that The poloxamer 407 accounts for 21.5% of the total weight of the preparation, the poloxamer 188 accounts for 6.5%, the N-(2-hydroxy)-propyl-3-trimethyl chitosan chloride accounts for 0.5-0.7%, and the proportion of pores with a diameter between 1-2 μm is at least more than 55%.